-1753895830833.webp&w=3840&q=75)
2025 NOSCM | CLL: Therapeutic Advances in 2025
0% Complete
Course Overview
Dr. Javier Pinilla-Ibarz highlighted 2025 CLL treatment shifts toward fixed-duration regimens. BTK+BCL-2 combos like Ibrutinib+Venetoclax showed 66% PFS in CAPTIVATE. MRD-guided Flare and triple-combo GAIA CLF 13 trials outperformed others, with SEQUOIA showing strong responses to Zanubrutinib+Venetoclax.
Course Content
This material is non-CME, no credits are available, and a certificate will not be provided upon completion.
Course Details
- Duration
- 0.00 hour
- Released
- Jul 31, 2025
- Last Review
- Jul 31, 2025
- Expires
- Jul 31, 2026
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Javier Pinilla-Ibarz, MD, PhD
Accreditation
NA
-1769197262927.webp&w=3840&q=75)
-1769197177699.webp&w=3840&q=75)